Skip to content
NIDA Center for Genetic Studies

NIDA Center for Genetic Studies

Providing Data and Biomaterials for Research on the Genetics of Addiction

  • About
  • Available Data
    • Smokescreen Datasets at dbGaP
    • Non-Smokescreen GWAS Datasets at dbGaP
    • The Cocaine Dependence Genetics Initiative
    • The Nicotine Dependence Genetics Initiative
    • The Opioid Dependence Genetics Initiative
    • The Opioid-Cocaine Dependence Genetics Initiative
    • The Polysubstance Dependence Genetics Initiative
    • The NicSNP Study
    • The NeuroSNP Project
  • Studies
    • All Studies
    • Cocaine Dependence
    • Nicotine Dependence
    • Opioid Dependence
    • Opioid-Cocaine Dependence
    • Polysubstance Dependence
    • Other Diseases
    • Clinical Trials Network Studies
    • Smokescreen Studies
  • Publications
  • Contact
  • Log In

Studies in the Clinical Trials Network (CTN)

NIDA’s Clinical Trials Network (CTN) is an enterprise in which NIDA, treatment researchers, and community-based service providers work toward new treatment options in community-level clinical practice.

Studies

Study 29 – Genetics Protocol of the Cocaine Use Reduction with Buprenorphine (CURB) Study; CTN-0048
Study 31 – Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT); CTN-0051
Study 32 – Achieving Cannabis Cessation-Evaluation of N-Acetylcysteine (ACCENT); CTN-0053
Study 37 – Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder; CTN-0068
Study 39 – Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT)
Study 40 – Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTREY); CTN-0098
Study 41 – Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy; CTN-0100
Study 44 – Randomized, Placebo-Controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder (CURB-2); CTN-0109
Study 45 – Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB); CTN-0110

Search

Contact Us

Proudly powered by WordPress